Earnings summaries and quarterly performance for C4 Therapeutics.
Executive leadership at C4 Therapeutics.
Andrew J. Hirsch
Detailed
President and Chief Executive Officer
CEO
JS
Jolie Siegel
Detailed
Chief Legal Officer and Secretary
KS
Kelly Schick
Detailed
Chief People Officer
KA
Kendra Adams
Detailed
Chief Financial Officer and Treasurer
LR
Leonard Reyno
Detailed
Chief Medical Officer
PM
Paige Mahaney
Detailed
Chief Scientific Officer
SB
Scott Boyle
Detailed
Chief Business Officer
Board of directors at C4 Therapeutics.
DG
Donna Grogan, M.D.
Detailed
Director
KC
Kenneth C. Anderson, M.D.
Detailed
Director
LB
Laura Bessen, M.D.
Detailed
Director
OH
Owen Hughes
Detailed
Director
RH
Ronald Harold Wilfred Cooper
Detailed
Chairman of the Board of Directors
SF
Stephen Fawell, Ph.D.
Detailed
Director
SH
Steven Hoerter
Detailed
Director
UK
Utpal Koppikar
Detailed
Director
Research analysts covering C4 Therapeutics.
Recent press releases and 8-K filings for CCCC.
C4 Therapeutics Outlines Strategic Milestones and Cash Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics plans to initiate the Phase 2 MOMENTUM trial for cemsidomide in Q1 2026 and a Phase 1b trial for cemsidomide in combination with elranatamab in Q2 2026.
- The company anticipates submitting a new drug application for cemsidomide and dexamethasone by year-end 2028 for potential accelerated approval in fourth line or later multiple myeloma.
- C4T's internal discovery strategy aims to deliver up to three investigational new drug applications by year-end 2028, focusing on inflammation, neuro-inflammation, and neuro-degenerative diseases.
- The company reports a cash runway to the end of 2028, providing funding through key value inflection points.
7 days ago
C4 Therapeutics Outlines Strategic Milestones for Cemsidomide and Discovery Pipeline, Projects Cash Runway to End of 2028
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (C4T) plans to initiate the Phase 2 MOMENTUM trial for cemsidomide in Q1 2026, targeting a new drug application submission by year-end 2028 for potential accelerated approval in relapsed/refractory multiple myeloma.
- A Phase 1b trial of cemsidomide in combination with elranatamab is scheduled to begin in Q2 2026, with a Phase 3 trial planned by early 2028.
- The company's internal discovery strategy aims to deliver up to three investigational new drug applications by year-end 2028, focusing on inflammation, neuro-inflammation, and neuro-degenerative diseases.
- C4T projects a cash runway to the end of 2028, providing funding through these key development milestones.
7 days ago
C4 Therapeutics Provides Update on Clinical Programs and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (CCCC) reported positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, in multiple myeloma patients, showing an overall response rate (ORR) of 36% across 72 patients and 53% at the 100 microgram dose, with a median duration of treatment of 9.3 months. The safety profile was differentiated, with no discontinuations due to safety and only 6% dose reductions.
- The cemsidomide study cohort included heavily pre-treated patients, with 100% triple-class exposed and 75% having received prior CAR T or T-cell engager therapy. The company believes this profile is competitive with other treatments like mezigdomide, particularly regarding tolerability.
- C4 Therapeutics has extended its cash runway through the end of 2028, which does not include potential milestone payments of up to $40 million over 2026 and 2027 from collaboration partners. This runway supports data readouts from the Phase 2 MOMENTUM study and the Phase 1b combination study with Elrexfio.
- A decision on advancing the CFT8919 program, an EGFR L858R degrader, is expected by the end of Q1 2026.
Dec 3, 2025, 8:25 PM
C4 Therapeutics Provides Update on Cemsidomide Clinical Development and Financial Runway
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (CCCC) presented positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, showing an Overall Response Rate (ORR) of 53% at the 100 microgram dose in heavily pre-treated multiple myeloma patients, with a favorable safety profile and 9.3 months median duration of treatment.
- The company plans to meet with the FDA later this month to align on the dose for the next phase of studies for cemsidomide, with enrollment expected to begin early next year. They anticipate a 40% ORR for the single-arm 4L+ study.
- C4 Therapeutics has a cash runway through the end of 2028, which funds data readouts from the Phase 2 MOMENTUM study and the Phase 1b combination study with Elrexfio. This runway does not include potential milestone payments of up to $40 million expected from collaboration partners over 2026 and 2027.
- The company also has an ongoing Phase 1 study for CFT8919, an EGFR L858R degrader, with a decision on advancing the program expected by the end of Q1 2026.
Dec 3, 2025, 8:25 PM
C4 Therapeutics Details Sensitamide Clinical Progress and Commercial Potential
CCCC
New Projects/Investments
Product Launch
Guidance Update
- C4 Therapeutics, a targeted protein degradation company, highlighted its lead program, Sensitamide, an IKZF1/3 degrader for multiple myeloma, which recently demonstrated a best-in-class profile with a 53% response rate in the 100 micrograms cohort in late-line refractory patients.
- The company plans to initiate new Sensitamide studies in early 2026, including a Phase 1B combination study with Pfizer's ELREXFIO and a non-randomized Phase 2 study targeting accelerated approval in late-line patients.
- C4 Therapeutics projects the commercial potential for Sensitamide to be between $2.5 billion and $4 billion, driven by its application in late-line multiple myeloma and in combination with BITEs in earlier treatment lines.
- The company has secured a financial runway through the end of 2028 following a recent financing.
Nov 12, 2025, 1:30 PM
CAMP4 Therapeutics Reports Q3 2025 Financial Results and Program Updates
CCCC
Earnings
New Projects/Investments
- CAMP4 Therapeutics reported a net loss of $15.1 million for the third quarter ended September 30, 2025.
- As of September 30, 2025, cash, cash equivalents, and marketable securities were $75.3 million, an increase from $39.1 million as of June 30, 2025.
- The company initiated GLP toxicology studies for its CMP-002 program for SYNGAP1-related disorders, with a Phase 1/2 clinical trial expected to begin as early as 2H 2026.
- An initial closing of $50 million in upfront proceeds from a private placement, with potential for up to $100 million, has extended the company's cash runway into 2027 to fund the SYNGAP1 program.
- CAMP4 plans to pursue partnerships for the continued development of its CMP-001 program for urea cycle disorders, following favorable safety and pharmacokinetics data from its Phase 1 clinical trial.
Nov 6, 2025, 9:05 PM
C4 Therapeutics Reports Q3 2025 Financial Results and Extends Cash Runway
CCCC
Earnings
Guidance Update
New Projects/Investments
- C4 Therapeutics reported a net loss of $32.2 million on revenue of $11.2 million for the third quarter ended September 30, 2025.
- The company's cash, cash equivalents, and marketable securities were $199.8 million as of September 30, 2025, which, combined with $125 million in gross proceeds from an October 2025 equity offering, is expected to fund operations until the end of 2028.
- Clinical data for cemsidomide in multiple myeloma demonstrated a 53% overall response rate at the highest dose level (100 µg) in the Phase 1 trial. The company plans to initiate a registrational Phase 2 MOMENTUM trial in Q1 2026 and a Phase 1b trial in combination with elranatamab in Q2 2026.
- C4 Therapeutics entered a clinical trial collaboration and supply agreement with Pfizer for cemsidomide and earned a $2 million milestone payment from Biogen.
Nov 6, 2025, 12:06 PM
C4 Therapeutics, Inc. Announces Underwritten Offering of Common Stock and Warrants
CCCC
- C4 Therapeutics, Inc. entered into an underwriting agreement for an offering of 21,895,000 shares of common stock, 28,713,500 pre-funded warrants, and 50,608,500 Class A and 50,608,500 Class B warrants.
- The combined offering price was $2.47 per share and accompanying warrants, or $2.4699 per pre-funded warrant and accompanying warrants.
- The company estimates net proceeds of approximately $117.0 million from the offering, which is expected to extend its cash runway to the end of 2028.
- If all warrants are cash exercised in full, the aggregate net proceeds to C4 Therapeutics, Inc. are expected to be $341.7 million.
- The offering is anticipated to close on October 17, 2025.
Oct 16, 2025, 9:29 PM
C4 Therapeutics Reports Positive Cemsidomide Phase 1 Data and Updates Clinical Development Plan
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics, Inc. announced positive data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, demonstrating a 53% Objective Response Rate (ORR) and 63% Clinical Benefit Rate (CBR) at the 100 µg QD dose level in heavily pre-treated patients as of September 10, 2025.
- The company plans to initiate a Phase 2 trial for cemsidomide + dexamethasone in 4L+ multiple myeloma in Q1 2026, with initial ORR data expected in 2H 2027. A Phase 1b trial for cemsidomide + elranatamab in 2L+ multiple myeloma is set to begin in Q2 2026, with data anticipated by mid-2027.
- Effective October 16, 2025, C4 Therapeutics terminated the sales agreement prospectus with TD Securities (USA) LLC, halting further sales of common stock under the agreement, after having issued 3,769,483 shares for approximately $9.6 million in gross proceeds as of June 30, 2025.
- Cemsidomide, an IKZF1/3 degrader, has a potential for $2.5 billion to $4 billion in peak revenue for label opportunities. The company also stated that CFT1946 will not advance beyond Phase 1, and they will seek partnership for the BRAF program.
Oct 16, 2025, 10:30 AM
C4 Therapeutics Presents Positive Cemsidomide Phase 1 Multiple Myeloma Data
CCCC
New Projects/Investments
Guidance Update
- C4 Therapeutics (C4T) presented positive Phase 1 clinical trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025.
- The trial demonstrated a 50% Overall Response Rate (ORR) at the highest dose level (100 µg) and a 40% ORR at the 75 µg dose level in heavily pre-treated RRMM patients, with a median Duration of Response (DOR) of 9.3 months across all dose levels.
- Cemsidomide exhibited a favorable safety profile with no discontinuations related to the drug and few dose reductions, supporting its suitability for combination regimens.
- C4T plans to initiate a Phase 2 registrational trial in Q1 2026 and a Phase 1b trial in Q2 2026, pursuing two distinct accelerated approval pathways for cemsidomide in RRMM.
- The company projects a potential $2.5 billion to $4 billion peak revenue opportunity for cemsidomide across these two market segments.
Sep 22, 2025, 10:41 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more